Brand name: MS-2 Step
MS-2 Step is a medicine containing the active ingredient(s) mifepristone, misoprostol. On this page you will find out more about MS-2 Step, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: mifepristone
Active ingredient in this medicine: misoprostol
Information for medicine and pack size:
MS-2 Step (4 x Gymiso tablets, 1 x Mifepristone (Linepharma) tablet), 1 pack
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
MS-2 Step is indicated in females of childbearing age for the medical termination of a developing intrauterine pregnancy, up to 63 days of gestation.,It is recommended that the duration of pregnancy (i.e., up to 63 days gestation) be confirmed by ultrasound. In the event that an ultrasound is not possible, extra caution should be exercised.,Ultrasound is also useful to exclude ectopic pregnancy.
Table of characteristics
| Active ingredient | |
|---|---|
| Medicine schedule |
One (1) Mifepristone Linepharma tablet and four (4) GyMiso tablets per MS-2 Step pack: Prescription Only Medicine, or Prescription Animal Remedy
|
Part 1
| Visual appearance | White, flat round tablet with ML debossed on one side and 200 on the other side. |
|---|---|
| Dosage Form | Tablet |
| Route of administration | Buccal |
Part 2
| Visual appearance | White to off-white, 11 mm diameter round biconvex tablet, with "MF" debossed on one side |
|---|---|
| Dosage Form | Tablet |
| Route of administration | Oral |
There is one type of pack available.
Pack type 1
| Type | Multiple containers |
|---|---|
| Storage temperature | Store below 25 degrees Celsius |
| Storage conditions | Protect from Light,Store in Original Container |
| Life time | 18 Months |
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Need more information?
These trusted information partners have more on this topic.
Found 32 results
MS-2 Step Combination pack - myDr.com.au
MS-2 Step Combination pack - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Metabolic syndrome - myDr.com.au
Metabolic syndrome is a condition that increases your risk of heart disease, stroke and diabetes. Lifestyle changes are the first step in its treatment.
Read more on myDr website
Slowly Dealing With It - CanTeen
Read a real story written by a young person about one of their parents having cancer. Learn more about help and support with CanTeen.
Read more on CanTeen website
Mifepristone Linepharma Tablets - myDr.com.au
Mifepristone Linepharma Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
How to use Nasonex - National Asthma Council Australia
Using your allergy nasal spray properly is important. This short video shows you how to use Nasonex.
Read more on National Asthma Council Australia website
Attention Deficit Hyperactivity Disorder in Children (Child ADHD) | myVMC
Attention deficit hyperactivity disorder, ADHD or ADD, is characterised by hyperactivity, short attention span and difficulty with concentration.
Read more on myVMC – Virtual Medical Centre website
Avonex Powder for injection - myDr.com.au
Avonex Powder for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Betaferon Powder for injection - myDr.com.au
Betaferon Powder for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Plegridy Solution for injection - myDr.com.au
Plegridy Solution for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
MS Mono Modified release capsules - myDr.com.au
MS Mono Modified release capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 20 results
Social Phobia
Social phobia, the fear of being judged negatively, is often not recognised because patients do not like to talk about their fears. It is also not recognized because clinicians either confuse it with shyness, or judge the secondary depression or substance dependence to be the primary disorder.
Read more on CRUfAD – Clinical Research Unit for Anxiety and Depression website
Transparency is good, independence from pharmaceutical industry is better! | Issue 4 | Volume 39 | Australian Prescriber
In Australia, the promotion of medicines to health professionals is controlled by self-regulatory schemes operated by the pharmaceutical industry.
Read more on Australian Prescriber website
The hazards of rapid approval of new drugs | Issue 1 | Volume 39 | Australian Prescriber
The attempt to speed up drug registration approvals could be detrimental for the appropriateness and safety of new medicines in Australia.
Read more on Australian Prescriber website
Treating hepatitis C whats new? | Issue 6 | Volume 38 | Australian Prescriber
Chronic hepatitis C infection causes cirrhosis, liver failure and hepatocellular carcinoma, and is the most common indication for liver transplantation....
Read more on Australian Prescriber website
Improving transparency in the pharmaceutical industry | Issue 4 | Volume 39 | Australian Prescriber
Medicines Australia represents many of the companies that develop new prescription medicines. It believes that companies interactions with Australian...
Read more on Australian Prescriber website
Managing acute pulmonary oedema | Issue 2 | Volume 40 | Australian Prescriber | Australian Prescriber
In an area of limited clinical evidence, what are the first-line treatments for acute pulmonary oedema?
Read more on Australian Prescriber website
Switching and stopping antidepressants | Issue 3 | Volume 39 | Australian Prescriber
Switching people from one antidepressant to another is commonly needed but can cause drug withdrawal symptoms, drug interactions and relapse in depression....
Read more on Australian Prescriber website
Paediatric pharmacokinetics anddrug doses | Issue 6 | Volume 39 | Australian Prescriber
Find out practical advice for calculating drug doses in children.
Read more on Australian Prescriber website
Prescribing for people in custody | Issue 5 | Volume 38 | Australian Prescriber
People who are, or have been, in custody often have multiple morbidities and multi-dimensional disadvantage. A thorough clinical evaluation and...
Read more on Australian Prescriber website
Bacterial skin and soft tissue infections | Issue 5 | Volume 39 | Australian Prescriber
Knowing when antibiotics are needed, and when to consider hospital referral are important in appropriate management of skin infections.
Read more on Australian Prescriber website
